受託製造厂商外包市场规模、份额、成长分析，按 CMO、CRO、地区和行业划分，2025-2032 年

Contract Development And Manufacturing Organization Outsourcing Market Size, Share, Growth Analysis, By CMO, By CRO, By Region - Industry Forecast 2025-2032

出版日期: 2025年01月01日 | 出版商:

SkyQuest | 英文 283 Pages | 商品交期: 3-5个工作天内

价格

简介目录

预计2023年全球合约开发和受託製造厂商（CDMO）外包市场规模为2286.3亿美元，从2024年的2432.6亿美元增长到2032年的3995.8亿美元，预计2025-2032年期间的复合年增长率将增长为6.4%。

由于对创新治疗的需求不断增加以及新药的复杂性不断增加，全球受託製造厂商外包市场正在经历显着增长。大大小小的製药公司与 CDMO 进行策略合作，以简化药物开发流程，消除对专门内部设施的需求。 CDMO 提供涵盖整个价值链的综合服务，从药物研究和临床前测试到原料药(API) 和最终产品製造。由于许多小型製药公司没有内部生产能力，这一趋势预计将加速。因此，与 CDMO 的伙伴关係对于高效、及时的药物开发和商业化将变得越来越重要。

前5名企业对比
主要企业市场定位（2024年）
主要市场参与者所采取的策略
近期市场趋势
公司市场占有率分析（2024年）
主要企业简介
产品系列分析
按细分市场分類的份额分析
收益与前一年同期比较（2022-2024）
主要企业简介
- 龙沙集团（瑞士）
- 康塔伦特（美国）
- 药明生物（中国）
- 三星生物製品（韩国）
- 齐格飞控股公司（瑞士）
- Fujifilm Diosynth BIoTTechnologies（日本）
- Recipharm AB（瑞典）
- 勃林格殷格翰（德国）
- 密理博西格玛（美国）
- Aenova 集团（德国）
- 法雷瓦（法国）
- Laurus 实验室（印度）
- 德尔法姆（法国）
- Piramal Pharma Solutions（印度）
- Almac集团（英国）
- 赢创工业（德国）
- Cambrex 公司（美国）
- 龙沙集团（瑞士）
- 帕森（美国）
- 药明康德（中国）

结论和建议

简介目录

Product Code: SQSG35J2008

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market size was valued at USD 228.63 billion in 2023 and is poised to grow from USD 243.26 billion in 2024 to USD 399.58 billion by 2032, growing at a CAGR of 6.4% during the forecast period (2025-2032).

The global contract development and manufacturing organization (CDMO) market is experiencing significant growth, driven by the rising demand for innovative therapeutics and the increasing complexity of new medicines. Pharmaceutical companies, both large and small, are strategically partnering with CDMOs to streamline their drug development processes, eliminating the need for specialized in-house facilities. CDMOs offer a comprehensive range of services that encompass the entire value chain, from drug research and preclinical trials to manufacturing active pharmaceutical ingredients (API) and finished products. This trend is expected to accelerate as many small pharmaceutical firms lack internal manufacturing capabilities. As a result, CDMO partnerships are set to become increasingly vital in ensuring efficient and timely drug development and commercialization.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market Segmental Analysis

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market is segmented by CMO, CRO and region. Based on CMO, the market is segmented into API Manufacturing, Finished Product Manufacturing, Packaging and Others. Based on CRO, the market is segmented into Early Phase Development Services, Clinical, Laboratory Service and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market

The global Contract Development and Manufacturing Organization (CDMO) outsourcing market is driven by the increased prevalence of chronic diseases driven by factors such as a growing westernized lifestyle, economic growth, and rising populations. Over 133 million Americans are affected by chronic conditions, representing over 40% of the population, and projections indicate that worldwide figures may reach 157 million by 2020. The market is further bolstered by significant investments from CDMOs looking to innovate and expand geographically, as seen in AbbVie's new API facility in Singapore. Additionally, partnerships between emerging companies like Cugene Inc. and established firms are facilitating market growth, particularly in innovative treatments for autoimmune and inflammatory diseases.

Restraints in the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market

The growth of the Global Contract Development and Manufacturing Organization (CDMO) outsourcing market is likely to be hindered by several key factors. Stringent government regulations and a decrease in the approval rates for various small molecules and biologics in developed regions play a significant role in this restraint. Furthermore, smaller-scale CDMOs that lack advanced equipment are at a higher risk of encountering process errors, compromising quality, and experiencing escalating costs. These issues collectively pose challenges that may adversely impact the overall expansion of the CDMO market during the forecast period, complicating operations and reducing competitiveness.

Market Trends of the Global Contract Development And Manufacturing Organization (Cdmo) Outsourcing Market

The global Contract Development and Manufacturing Organization (CDMO) outsourcing market is witnessing significant fragmentation driven by the rising demand for rapid innovations and efficient process solutions in drug development. As pharmaceutical companies seek to streamline operations and enhance productivity, CDMOs are increasingly partnering with both small and large pharmaceutical and biotech enterprises, as well as life sciences corporations. This trend not only bolsters their service offerings but also fosters collaboration and knowledge-sharing, ultimately leading to improved operational efficiencies and accelerated time-to-market for new therapeutics. This dynamic environment is characterized by strategic alliances, technological advancements, and a focus on customized solutions to meet diverse client needs.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Case Studies
Customer & Buying Criteria Analysis

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by CMO & CAGR (2025-2032)

Market Overview
API Manufacturing
Finished Product Manufacturing
- Solid Dosage Forms
- Injectables
- Others
Packaging
Others

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size by CRO & CAGR (2025-2032)

Market Overview
Early Phase Development Services
- Chemistry, Manufacturing and Controls (CMC)
- Preclinical Service
- Discovery
Clinical
- Phase 1
- Phase 2
- Phase 3
- Phase 4
Laboratory Service
Others

Global Contract Development And Manufacturing Organization (CDMO) Outsourcing Market Size & CAGR (2025-2032)

North America (CMO, CRO)
- US
- Canada
Europe (CMO, CRO)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (CMO, CRO)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (CMO, CRO)
- Brazil
- Rest of Latin America
Middle East & Africa (CMO, CRO)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Siegfried Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fujifilm Diosynth Biotechnologies (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB (Sweden)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
MilliporeSigma (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aenova Group (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Fareva (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Laurus Labs (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Delpharm (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Piramal Pharma Solutions (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Almac Group (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Evonik Industries (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cambrex Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lonza Group (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patheon (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi AppTec (China)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments